Adma Biologics reported $3.66M in Gross Profit on Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Adma Biologics ADMA:US $ 3.66M 3.28M
Agile Therapeutics AGRX:US 234K 1.66M
Alnylam Pharmaceuticals ALNY:US $ 177.63M 43.24M
Biocryst Pharmaceuticals BCRX:US $ 49.68M 2.95M
China Cord Blood CO:US 269.92M 2.46M
Takeda 4502:JP Y 564909M 54981M